Nektar Therapeutics
NKTR
136 hedge funds and large institutions have $1.16B invested in Nektar Therapeutics in 2013 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 51 increasing their positions, 47 reducing their positions, and 21 closing their positions.
11% more capital invested
Capital invested by funds: $1.05B → $1.16B (+$111M)
9% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less call options, than puts
Call options by funds: $4.46M | Put options by funds: $4.61M
4% less funds holding
Funds holding: 142 → 136 (-6)
19% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$27.4M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$12.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10.1M |
| 4 |
Bank of New York Mellon
New York
|
+$8.2M |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$5.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Meditor Group
Hamilton,
Bermuda
|
-$15.1M |
| 2 |
AG
Artal Group
Luxembourg
|
-$7.53M |
| 3 |
PC
PointState Capital
New York
|
-$6.01M |
| 4 |
ICM
IronBridge Capital Management
Oakbrook Terrace,
Illinois
|
-$5.92M |
| 5 |
Barclays
London,
United Kingdom
|
-$5.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Two Sigma Investments
New York
| – | -$159K | -1,014 | Closed |
|
|
CAM
152
Capstone Asset Management
Houston,
Texas
| – | -$137K | -874 | Closed |
|
|
PP
153
Paloma Partners
Greenwich,
Connecticut
| – | -$105K | -667 | Closed |
|
|
QIM
154
Quantitative Investment Management
Charlottesville,
Virginia
| – | -$104K | -667 | Closed |
|
|
FANJ
155
Financial Architects (New Jersey)
Marlton,
New Jersey
| – | -$31K | -200 | Closed |
|
|
SO
156
STRS Ohio
Columbus,
Ohio
| – | -$14K | -87 | Closed |
|
|
PG
157
PEAK6 Group
Chicago,
Illinois
| – | -$5K | -60 | Closed |
|
NKTR Hedge Fund Activity: Q4 2013 in Review
136 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q4 2013, worth a combined $1.16B — up 11% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of NKTR and 17 opened new positions — a net loss of 4 holders — while 47 trimmed existing stakes and 51 added.
The largest buyer was Primecap Management, adding an estimated $27.4M. The largest seller was Meditor Group, exiting entirely with an estimated $15.1M sold.
- 136 institutional investors held Nektar Therapeutics (NKTR) as of Q4 2013, down from 142 in Q3 2013.
- Funds reported $1.16B of Nektar Therapeutics stock for Q4 2013, up 11% quarter-over-quarter.
- 17 funds opened new Nektar Therapeutics positions in Q4 2013 and 21 closed out, a net change of -4 holders.
- The largest Nektar Therapeutics buyer in Q4 2013 was Primecap Management, an estimated $27.4M added.
- The largest Nektar Therapeutics seller in Q4 2013 was Meditor Group, an estimated $15.1M sold.
Based on aggregated 13F filings for Q4 2013.